Citing promising but highly caveated early models, the genetics company announced a partnership with HealthEx to import clinical files. However, experts warn that the correlation between user spit and usable medical advice has not yet been subjected to peer review.
SAN FRANCISCO — Citing promising but heavily caveated early data, 23andMe announced Tuesday at the STAT Breakthrough Summit West that it will partner with HealthEx to import users’ clinical medical records, initiating a massive observational cohort study to determine if actual doctor visits can render the company's mail-in spit tubes medically relevant.
Researchers caution that the mechanism of action for the new feature remains poorly understood. While preliminary phase-one rollout models indicate a strong association between combining a patient’s genetic predisposition to restless leg syndrome with their actual diagnostic history, experts emphasize that this correlation does not necessarily imply causation of any actionable healthcare outcome. Furthermore, the findings regarding the data's utility have not yet been subjected to double-blind peer review.
We are seeing some indications that importing a user's comprehensive HealthEx file alongside their genetic data may produce a statistically significant increase in targeted pharmaceutical advertisements, but the confidence intervals are extremely wide.
Methodological concerns remain a primary hurdle for the efficacy of the program. A recent editorial published in The Lancet noted that 23andMe’s sample size is inherently biased toward a highly unrepresentative cohort of individuals willing to upload their entire clinical history to a consumer application currently grappling with significant market volatility. Analysts further warned of a known adverse side effect in which longitudinal health data experiences unencrypted exposure to the dark web, though researchers stress that such breaches currently only affect a subset of the cohort and further longitudinal studies are required to assess the full risk.
At press time, the medical community recommended a standard dose of caution regarding the feature's long-term prognosis. Users are strongly advised to consult a board-certified primary care physician before assuming that cross-referencing their genetic likelihood of cilantro aversion with their real-time cholesterol lab results will successfully treat any underlying conditions.